Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
mFOLFIRINOX Does Not Significantly Improve Survival Vs mFOLFOX6 in HER2– Metastatic Gastric/GEJ Adenocarcinoma
July 6th 2025, 6:06pm
ESMO Gastrointestinal Cancers Congress
IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.
RATIONALE-306 Subgroup Data Further Support First-line Tislelizumab/Chemo in Locally Advanced ESCC
July 5th 2025, 8:45pm
ESMO Gastrointestinal Cancers Congress
Tislelizumab plus chemotherapy improves efficacy vs chemotherapy alone in locally advanced ESCC, including those with PD-L1 TAP of 5% or higher.
Trifluridine/Tipiracil Numerically Improves DFS After Curative Resection in ctDNA+ CRC
July 5th 2025, 5:55pm
ESMO Gastrointestinal Cancers Congress
Treatment with trifluridine/tipiracil led to an improvement in disease-free survival in ctDNA-positive colorectal cancer after curative resection.
ctDNA-Guided Surveillance Leads to Increased Curative-Intent Treatment After Recurrence in Nonmetastatic CRC
July 5th 2025, 5:29pm
ESMO Gastrointestinal Cancers Congress
ctDNA monitoring led to earlier recurrence detection and increased use of curative-intent treatment after recurrence in nonmetastatic colorectal cancer.
Dr Finn on Adding Tiragolumab to Atezolizumab and Bevacizumab in Locally Advanced or Metastatic HCC
July 5th 2025, 9:00am
ESMO Gastrointestinal Cancers Congress
Richard Finn, MD, discusses the addition of tiragolumab to atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
Dr García-Carbonero on Outcomes With Fruquintinib in R/R mCRC by Metastatic Sites
July 5th 2025, 8:48am
ESMO Gastrointestinal Cancers Congress
Rocío García-Carbonero, MD, discusses a subgroup analysis of fruquintinib vs placebo in patients with refractory metastatic colorectal cancer.
Real-World Analysis Sheds Light on Fruquintinib Use in Later-Line Metastatic CRC
July 4th 2025, 6:46pm
ESMO Gastrointestinal Cancers Congress
A real-world study in Portugal showed fruquintinib displayed a manageable safety profile and an efficacy trend in refractory colorectal cancer.
Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC
July 4th 2025, 6:19pm
ESMO Gastrointestinal Cancers Congress
Nivolumab plus ipilimumab maintained an ORR benefit across subgroups of Chinese patients with unresectable hepatocellular carcinoma.
Quantitative Vessel Tortuosity Shows Potential as Biomarker for Antiangiogenic Activity With Fruquintinib in mCRC
July 4th 2025, 5:28pm
ESMO Gastrointestinal Cancers Congress
Quantitative vessel tortuosity features were able to detect the VEGFR inhibitory mechanism of fruquintinib in metastatic colorectal cancer.
Survival Benefit, Neutropenia Risk Influence Third-Line Treatment Preferences for mCRC in Germany and the UK
July 4th 2025, 4:38pm
ESMO Gastrointestinal Cancers Congress
A survey of UK and German physicians found that OS gains were needed to accept increased toxicities or treatment burden with third-line regimens in mCRC.
Dr Schlechter on Updated Data for Botensilimab Plus Balstilimab in MSS mCRC
July 4th 2025, 1:43pm
ESMO Gastrointestinal Cancers Congress
Benjamin L. Schlechter, MD, discusses efficayc and safety of botensilimab in combination with the anti–PD-1 antibody balstilimab in mCRC.
Subgroup Analysis Supports Encorafenib Plus Cetuximab/mFOLFOX6 as New SOC for BRAF V600E+ mCRC
July 4th 2025, 1:30pm
ESMO Gastrointestinal Cancers Congress
Post hoc analyses compared encorafenib plus cetuximab and mFOLFOX6 with different BREAKWATER control arm regimens.
Fruquintinib Demonstrates Clinical Benefit in mCRC Irrespective of Metastatic Sites at Baseline
July 4th 2025, 1:30pm
ESMO Gastrointestinal Cancers Congress
A post hoc subgroup analysis of FRESCO-2 shed light on the safety and efficacy of fruquintinib by metastatic site in metastatic colorectal cancer.
Dr Janjigian on PROs for Perioperative Durvalumab Plus FLOT in Gastric/GEJ Adenocarcinoma
July 4th 2025, 10:34am
ESMO Gastrointestinal Cancers Congress
Yelena Y. Janjigian, MD, discusses patient-reported outcomes and QOL assessments for durvalumab plus FLOT in resectable gastric/GEJ adenocarcinoma.
On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC
July 3rd 2025, 10:56pm
ESMO Gastrointestinal Cancers Congress
TACE plus atezolizumab and bevacizumab may represent effective option for untreated intermediate-to-high tumor burden unresectable HCC.
TTFields Plus Chemo Improves QOL, Delays Time to Pain Deterioration in Locally Advanced Pancreatic Adenocarcinoma
July 3rd 2025, 8:01pm
ESMO Gastrointestinal Cancers Congress
The addition of TTFields to chemotherapy improved quality of life and delayed time to pain deterioration in locally advanced pancreatic cancer.
Nivolumab Plus Ipilimumab Improves HRQOL Vs Nivolumab Alone in MSI-H/dMMR mCRC
July 3rd 2025, 4:22pm
ESMO Gastrointestinal Cancers Congress
CheckMate 8HW data show ipilimumab plus nivolumab improved PFS vs nivolumab alone while maintaining HRQOL.
Perioperative Durvalumab/FLOT Does Not Diminish PROs in Resectable Gastric/GEJ Adenocarcinoma
July 3rd 2025, 4:01pm
ESMO Gastrointestinal Cancers Congress
Durvalumab plus FLOT did not lead to differences in patient-reported outcomes vs placebo plus FLOT in resectable gastric/GEJ cancer.
Dr O’Reilly on the Rapidly Evolving Role of Local Therapy in Metastatic Pancreatic Cancer
July 3rd 2025, 3:24pm
ESMO Gastrointestinal Cancers Congress
Eileen M. O’Reilly, MD, discusses the rapidly evolving role of local therapy in the management of advanced/metastatic pancreatic cancer.
Dr Weinberg on the Efficacy of BXCL701 Plus Pembrolizumab in Pretreated, Metastatic PDAC
July 3rd 2025, 9:46am
ESMO Gastrointestinal Cancers Congress
Benjamin A. Weinberg, MD, FACP, discusses preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC.